COVID-19 IgM/IgG Ƙwararren Ƙwararren Ƙwararru
Gabatarwar Samfur
Virusee® COVID-19 IgM/IgG Lateral Flow Assay shine maganin rigakafi na gefe wanda ake amfani dashi don gano in vitro qualitative detection novel coronavirus (SARS-CoV-2) IgM / IgG antibodies a cikin venipuncture na ɗan adam duka jini, plasma, da samfuran serum.
Novel coronavirus tabbataccen ƙwayar cuta ce ta RNA mai ɗauri ɗaya.Ba kamar kowane sanannen coronavirus ba, yawan masu rauni na Novel Coronavirus gabaɗaya yana da sauƙin kamuwa da shi, kuma yana da haɗari ga tsofaffi ko mutanen da ke da cututtukan asali.IgM/IgG antibodies tabbatacce alama ce mai mahimmanci na cututtukan cututtukan coronavirus.Gano sabbin ƙwayoyin rigakafi na musamman na coronavirus zai taimaka ganewar asibiti.
Halaye
| Suna | COVID-19 IgM/IgG Ƙwararren Ƙwararren Ƙwararru |
| Hanya | Ƙididdigar Ƙwararren Ƙwararru |
| Nau'in samfurin | jini, jini, jini |
| Ƙayyadaddun bayanai | Gwaje-gwaje 20/kit |
| Lokacin ganowa | 10 min |
| Abubuwan ganowa | CUTAR COVID-19 |
| Kwanciyar hankali | Kit ɗin yana da ƙarfi don shekara 1 a 2-30 ° C |
Amfani
- Mai sauri
Sami sakamako a cikin mintuna 10 - Sauƙi
Sakamakon karatun gani, mai sauƙin fassara
Hanya mai sauƙi, ba tare da aiki mai rikitarwa ba
- Ajiye farashi
Za'a iya jigilar samfura da adanawa a zafin daki, rage farashi - Ƙananan haɗari
Gwajin samfurin jini, rage haɗarin tsarin samfur - Dace don dubawa akan-site, gefen gado, mara lafiya
Fage da ka'ida
Littafin labari na coronavirus, mai tsananin ciwo na numfashi na coronavirus (SARS-CoV) -2, an gano shi azaman mai haifar da cututtukan coronavirus 2019 (COVID-19).Hukumar Lafiya ta Duniya (WHO) ta kira wannan cuta ta gaggawar lafiyar jama'a da ta damu duniya.
COVID-19 yana hari na sama da ƙananan tsarin numfashi kuma yana haifar da alamun mura a yawancin masu kamuwa da cutar.Kodayake yawancin marasa lafiya na COVID-19 suna fuskantar alamu masu laushi kawai, wasu marasa lafiya suna da mummunan alamun da ke haifar da lalacewar huhu.Zaɓuɓɓukan jiyya don COVID-19 suna da iyaka kuma adadin yawan mace-mace da WHO ta kiyasta ya kusan kashi 2.9%.Kodayake rigakafin rigakafin COVID-19 na iya kasancewa a ƙarshe, sai dai idan an sami isasshen rigakafin garken garken, COVID-19 na iya haifar da babbar cuta da mace-mace a cikin shekaru masu zuwa.
Bayan shan wahala daga kamuwa da cuta, yana da yawa don samar da amsawar antibody akan wani takamaiman cuta.Da wuri bayan kamuwa da cuta (yawanci bayan mako na farko), rukunin ƙwayoyin rigakafi da aka sani da immunoglobulin M (IgM) suna tasowa, kodayake waɗannan ba yawanci suna daɗewa ba.Daga baya, bayan makonni 2-4 na farko bayan kamuwa da cuta, IgG, wanda ya fi ƙarfin rigakafi, an samar da shi.
Nazarin ya gano cewa ƙwayoyin rigakafi da aka yi niyya na RBD sune kyawawan alamomin kamuwa da cuta na baya da na baya-bayan nan, cewa ma'aunin isotype na daban na iya taimakawa bambance tsakanin cututtukan kwanan nan da tsofaffi.Gano ƙwayoyin rigakafi na IgM da IgG akan SARS-CoV-2 yana da yuwuwar mahimmanci don kimanta tsananin da hasashen COVID-19, har ma da haɓaka daidaiton gano gwajin acid na nukiliya.
Gano SARS-CoV-2 IgM da IgG yana da matukar mahimmanci don tantance yanayin COVID-19.Gano sinadarin Nucleic acid haɗe tare da maganin ƙwayar cuta na SARS-CoV-2 na iya zama mafi kyawun nunin dakin gwaje-gwaje don gano kamuwa da cutar SARS-CoV-2 da jumla da tsinkayar hasashen COVID-19.
Tsarin gwaji
Bayanin oda
| Samfura | Bayani | Lambar samfur |
| VMGLFA-01 | 20 gwaji/kit, tsarin kaset | CoVMGLFA-01 |
